Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …

In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …

Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

Biomedical polymers have been extensively developed for promising applications in a lot of
biomedical fields, such as therapeutic medicine delivery, disease detection and diagnosis …

Cancer is now considered a tumor microenvironment (TME) disease, although it was
originally thought to be a cell and gene expression disorder. Over the past 20 years …

Over the past decade, preclinical and clinical research have confirmed the essential role of
interferons for effective host immunological responses to malignant cells. Type I interferons …

Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been
substantially improved with the emergence of novel therapeutic agents, such as proteasome …

Immune checkpoint inhibitors have revolutionized the treatment of patients with advanced-
stage metastatic melanoma, as well as patients with many other solid cancers, yielding long …

The immune checkpoint pathway consisting of the cell membrane-bound molecule
programmed death protein 1 (PD-1) and its ligand PD-L1 has been found to mediate …

Cancer immunotherapy by educating or stimulating patients' own immune systems to attack
cancer cells has demonstrated promising therapeutic responses in the clinic. However …